相关实验视频

Updated: Jul 7, 2025

Color Spot Test As a Presumptive Tool for the Rapid Detection of Synthetic Cathinones

Color Spot Test As a Presumptive Tool for the Rapid Detection of Synthetic Cathinones

Published on: February 5, 2018

synephrine及其衍生化合物A:常见和特定的生物效应

Svetlana A Dodonova¹, Ekaterina M Zhidkova², Alexey A Kryukov¹

¹Research Institute of Experimental Medicine, Department of Pathophysiology, Kursk State Medical University, 305041 Kursk, Russia.

International journal of molecular sciences

|December 23, 2023

概括

辛色化合物synephrine是一种流行的减肥补充剂. 本综述探讨了它的生物作用,抗炎和抗癌作用,以及开发新的非类固醇选择性葡萄糖皮质体受体激动剂 (SEGRA) 的潜力.

科学领域:

药理学药理学是指药理学的学科.
自然产品化学化学
分子生物学分子生物学

背景情况:

赛内是苦中的关键植物化学物质,用于减肥的食补充剂.
它的生物点和作用机制对于理解其影响至关重要.
选择性葡萄糖皮质体受体激动剂 (SEGRA) 与传统葡萄糖皮质体相比,具有较少的副作用,提供治疗效益.

研究的目的:

为了审查synephrine的生物学,分子点和药理学特性.
为了比较synephrine与其代谢物,化合物A (CpdA),一个SEGRA.
探索synephrine作为新型非类固醇SEGRA的模板的潜力.

主要方法:

对synephrine的起源,化学和药理学的文献评论.
关于synephrine抗炎和抗癌活性的体外和动物研究的分析.
对synephrine和CpdA分子标和作用的比较评估.

主要成果:

在临床前模型中,synephrine 呈现出抗炎和抗癌特性.
赛内林与SEGRA化合物A具有结构上的相似之处.
提供了关于synephrine安全药理学特征的见解.

结论:

赛内弗林具有多种药理作用,包括抗炎和抗癌作用.
赛内林作为一种潜在的支架,用于开发新的非类固醇SEGRAs.
对synephrine治疗应用的进一步研究是有必要的.

关键词:

这就是CpdAA的意思.在β-上腺素受体.癌症癌症癌症癌症癌症心血管系统的心血管系统葡萄糖皮质类药物是什么这是一种炎症炎症炎症炎症.代谢障碍代谢障碍代谢障碍选择性葡萄糖皮质激素受体激活剂赛内弗林 (synephrine) 是一种可怕的药物.

更多相关视频

A Convenient Method for Extraction and Analysis with High-Pressure Liquid Chromatography of Catecholamine Neurotransmitters and Their Metabolites

A Convenient Method for Extraction and Analysis with High-Pressure Liquid Chromatography of Catecholamine Neurotransmitters and Their Metabolites

Published on: March 1, 2018

Rapid Model to Evaluate the Anti-Obesity Potential of a Combination of Syzygium aromaticum Clove and Cuminun cyminum Cumin on C57BL6/j Mice Fed High-Fat Diet

Rapid Model to Evaluate the Anti-Obesity Potential of a Combination of Syzygium aromaticum Clove and Cuminun cyminum Cumin on C57BL6/j Mice Fed High-Fat Diet

Published on: July 31, 2021

相关概念视频

Adrenergic Agonists: Mixed-Action Agents

Adrenergic Agonists: Mixed-Action Agents

Mixed-action adrenergic agonists, like ephedrine and pseudoephedrine, directly and indirectly affect adrenergic receptors. These agents stimulate adrenoceptors and indirectly release stored neurotransmitters, amplifying the adrenergic response.
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...

Adrenergic Agonists: Direct-Acting Agents

Adrenergic Agonists: Direct-Acting Agents

Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...

Adrenergic Agonists: Indirect-Acting Agents

Adrenergic Agonists: Indirect-Acting Agents

Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...

Drugs Affecting Neurotransmitter Release or Uptake

Drugs Affecting Neurotransmitter Release or Uptake

Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...

Drugs Acting on Autonomic Ganglia: Stimulants

Drugs Acting on Autonomic Ganglia: Stimulants

Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating...